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Introduction
Prostate cancer (PCa) is the most common cancer type 
among the male population of Europe and it is on the third 
place in the structure of oncological diseases. In 2012, about 
417,000 new cases of cancer were diagnosed, out of which 
PCa represents 12% of the total number of cases [1]. Castra-
tion-resistant prostate cancer (CRPC) is second among the 
main causes of death from malignant diseases in representa-
tives of the stronger sex [2]. 
According to pathoanatomical studies, it was found that 
prostate cancer has a long period of asymptomatic growth. 
It sometimes takes several decades before the appearance of 
a clinically pronounced form. In the opinion of Sakr W. A. et 
al. [3], small foci of histological cancer were detected in 27% 
and 34% of 40 and 50-year-old men, respectively. According 
to Breslow N., et al. 1977, Barry M. J. 2001 [4-5] , prostate 
cancer appears in 60% - 80% of men older than 70 years and 
only in 0.1% of individuals aged under 50 years [6].
Despite such a high prevalence, the latent form of pros-
tate cancer becomes clinically significant only in 10% of 
cases [7]. Most scientists share the view that late detection 
of prostate cancer is associated with a prolonged asymp-
tomatic evolution of the disease. The study of the dynamics 
of cancerous tumours growth has shown that ¾ of time for 
their development falls on the preclinical period [8].  In the 
opinion of B. Ya. Alekseev et al., metastases are found in 60-
80% of patients with primary prostate cancer [9].
Until the 1970s (pre-screening era), in Western coun-
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Abstract
Background:  The neurotransmitters (epinephrine and norepinephrine) of the sympathetic nervous system that perform numerous cellular and tissue 
functions contribute to tumor growth during the early stages of development. At the same time, these bioactive substances act as mediators of the descending 
antinociceptive system that cause inhibition of pain at the suprasegmental and segmental levels of the neurotransmission. Later studies point to the 
involvement of afferent sensory neurons in tumor process. The functionality of these structures can be changed due to the structural features caused by 
genetic disorders of myelin. In addition to that, tumor augmentation of sensory neurons endings leads to the involvement of myeloid-derived suppressor 
cells in the affected area and the creation of an immunosuppressive microenvironment. At the same time, in the secondary inflammatory process, various 
enzymes that change the cellular matrix and cause invasion and metastasis are released.  In addition to sensitizing cytokines, immunocompetent cells 
– macrophages, neutrophils, lymphocytes – can also produce opioid peptides that target the desensitization of peripheral nociceptors. Opioid peptides 
inhibit the excitability of sensory nerves without central unwanted side effects such as depression of breathing, clouding of consciousness, or addiction. 
This peripheral antinociceptive system with ICC may allow the neoplasm to remain asymptomatic for a while. The changes in afferent impulses at the 
central level in oncopathology can also be associated with those in the functionality of Toll-like receptors.
Conclusions:  Taking into account the aforementioned literature data about oncogenesis, it may be assumed the presence of a new complex pathogenetic 
pattern that ensures the asymptomatic evolution of prostate cancer. A better coverage of this data may facilitate further search for early markers of the disease.
Key words: prostate, cancer, asymptomatic.
tries, the late stage (metastatic prostate cancer) in primary 
diagnosis was observed in more than 50% of cases. In the 
present period, 10 to 20% of patients also have distant me-
tastases at the time of diagnosis [10]. 
Authors who have studied the features of PCa with fa-
tal outcome provide similar data. According to them, PCa 
metastases were identified in 56% of patients who died of 
prostate cancer [11]. The differential diagnosis of PCa is car-
ried out with the other prostate diseases, previous ineffec-
tive drug therapy of LUTS [12].
Analyzing the scientific data on the tumour microenvi-
ronment and its interaction with various macroorganism 
systems, some features can be outlined, which may show 
that a tumour can remain asymptomatic for a long time. 
Interaction of nerves and tumors
Experimental models have relatively recently shown the 
involvement of nerve fibres in the tumour tissue in prostate 
cancer [13]. Cancer cells can invade nerves surrounding the 
tumour by expression and secretion of nerve growth factor 
(NGF) [14]. The ability of NGF to regulate expression and 
production of neurotransmitters, as well as modulation of 
synaptic activity [15] were also detected. In their turn, anti-
hyperalgesic and analgesic effects may be accompanied by 
changes in synaptic transmission [16-17]. 
The original work on the interaction of malignant neo-
plasm and those involved in the pathological process of af-
ferent (sensory) neurons was performed by the authors [18]. 
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In the course of the study, they revealed that there is tumor 
augmentation of endings of sensory neurons leading to hy-
perproduction of chemokines by nerve cells of the dorsal 
root ganglia (DRG). According to scientists, the formed 
tumor-neuronal-immune axis promotes the involvement 
of myeloid-derived suppressor cells (MDSC) in the affected 
area and the creation of an immunosuppressive microenvi-
ronment. 
According to Magnon C. et al. [13], the nerve fibres of 
the sympathetic nervous system “contribute” to prostate 
cancer in the early stages of development by producing the 
neurotransmitter “norepinephrine” (NE). Observations 
of scientists [19-20] point to the dominant role of norepi-
nephrine locally secreted by nerve fibres in controlling be-
ta-adrenergic effects on tumour development. On the other 
hand, NE is also a mediator of the descending antinocicep-
tive system by activation of adrenergic receptors that causes 
inhibition of pain at the suprasegmental and segmental lev-
els of the neurotransmission [21].
Abnormal architectonics of tumour tissue is reflected 
in the components of neurovascular structures. According 
to some researchers [13, 14, 22], differences between the 
growth of nerve cells in normal tissue and tumours can be 
detected. In a tumour, the axon lengthens, whereas in nor-
mal tissue the cell body of the neuron thickens. Moreover, 
some authors report the correlation between the density of 
nerve fibres within prostate carcinoma and the degree of its 
aggressive behavior [23, 14].
Studies on prediction of upgrading and disease upstag-
ing in low-risk prostate cancer identify a panel of three 
genes which expression significantly affects the aggressive 
behavior of the disease [24]. One of these genes, PMP22, 
encodes glycoprotein contained in ~ 5% of the total myelin 
protein in the nervous system [25, 26], while genetic defects 
related to PMP22 are also associated with peripheral neu-
ropathy [27]. The above features may affect the transaxonal 
transport. According to the author [28], the violation of the 
latter mechanism can lead to a decrease of mediator content 
in the presynaptic structures and create an analgesic effect. 
This principle – decrease of mediator content in presynaptic 
structures – underlies the action of anaesthetics.
Features of the metabolism of blastemal cells and 
nociception
The atypism of tumour tissue, as noted above, affects the 
morphology of the constituent nerve structures, a fact that 
may also change their functionality. Further, we will present 
some features of blastoma cells that may influence the inten-
sity of pain impulses from the oncologic focus.
An increase in the proliferative activity of the cell in re-
sponse to mitogenic stimulation is accompanied by a large-
scale dynamic increase in the concentration of cytosolic 
calcium [29]. For example, the authors [30], examining the 
level of cytosolic calcium (Ca2+) oscillations in oesophageal 
squamous cell carcinoma (ESCC), have noted significantly 
higher indices of this parameter in blastemal cells in com-
parison to the control ones – 76% versus 26%, respectively.
The change in intracellular calcium concentration in-
volves the inducing of a whole cascade of intracellular 
events, including the activation of transcriptional and apop-
totic mechanisms [31, 32, 33].
The possibility to avoid the inclusion of the mechanisms 
of apoptosis provides one of the fundamental conditions of 
oncogenesis – the possibility of uncontrolled division. Tu-
mour cells can avoid apoptosis by decreasing the cytosolic 
calcium concentration [34, 35]. The latter phenomenon can 
be achieved by changing the functionality of the membrane 
Ca2 + ion channels [36]. Some features of these structures 
have been revealed in the course of PCa [37, 38].
TRPM8 is one of the Ca2 + ion channel groups, and has 
been first identified in PCa cells, but it was found later that 
TRPM8 channels are also expressed in nociceptive neurons 
[39].
Some interesting features are noted by increasing the 
range of studies in terms of analyzing the consequences of 
disruption of the calcium channels. According to the feed-
back mechanism in the peripheral painful systems of Ca2 
+, the ion channels are activated low and inactivated by a 
high concentration of cytosolic calcium [40]. According to 
the author [41], the suppression of calcium currents by 20-
90% from the initial values (depending on the type) is one of 
the components of the local anaesthetic effect of tetracaine. 
Scientists [42, 43, 44, 45] provide similar data – blocking ion 
channels can ensure terminating the action potential (AP), 
with the establishment of local anesthesia. In this context, 
the authors’ conclusions [46] that the decrease in the trans-
membrane Ca + transport facilitates the establishment of 
analgesia also enhances the effect of opioids.
Reduction of the axon excitability and nerve endings 
in some neurons has also been observed in the hyperfunc-
tion of calcium-activated chloride channels (CaCCs). These 
structures are expressed in excitable and epithelial cells, en-
suring stabilization of the resting membrane potential and 
cell volume regulation. The number of functioning nerve 
endings is regulated by modulating conductivity of chlo-
rine. For example, the activation of CACCs reduces the nor-
mal excitability and facilitates the establishment of a block 
for carrying out the action potential in the branch node [47, 
48].
Investigating the impact of neuroendocrine differentia-
tion in PCa cells on the characteristics of the volume-regu-
lated chloride channels, Lazarenko R. N. [49] has revealed a 
2-fold excess of this parameter in comparison to the control 
level.
Some of the above theoretical considerations have been 
practically confirmed in various experiments on animals. It 
was found that modulation of both central and peripheral 
ion channels could significantly change the pain sensitivity 
threshold. Researchers [51, 52, 53] have established signs of 
a decrease in pain sensitivity in experimental rodents with 
impaired permeability of calcium channels. An interesting 
fact is that the increased Ca2+ influx is considered critical 
for the transmission of persistent but not short-term pain 
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impulses [54]. The noted features can be manifested in can-
cer patients because of local ionic disorders.
An atypical metabolism with a predominance of gly-
colysis is one of the main logos of carcinogenesis. During 
rapid replication of tumour cells, it is necessary to have a 
huge amount of biomaterial for the synthesis of cellular 
structures, which to some extent can be provided by an-
aerobic glycolysis [55]. At the same time, this feature of the 
exchange is ineffective in terms of ATP production [56]. The 
production of ATP is only 50% of the total level in the mi-
tochondria of malignant cells, whereas in conventional cells 
this figure reaches 90% [57]. The latter feature may possibly 
affect the level of this substrate in blastemal cells, followed 
by a violation of purinergic signal transmission between 
neurons in the tumour environment and its microenviron-
ment [58]. According to Fields R.D., et al., the release of 
neurotransmitters in the peripheral nervous system (PNS) 
occurs with the assistance of ATP and adenosine [59], and 
also processing of sensory information [60] is provided by 
means of these mediators by purinergic receptors.
Perversion of metabolic processes characteristic to can-
cer cell degeneration is accompanied by a decreased activity 
or the absence of certain specialized enzymes inherent in 
normal tissues (arhipase, catalase, cytochrome oxidase, cy-
tochrome c, esterase, etc.) [61]. For example, researchers [62, 
63] indicate a decreased expression of Na +, K + -ATPase in 
some carcinomas. Na+ /K+ -ATPase is a necessary enzyme 
to maintain sufficient activity of the Na+/K+) pump – one of 
the key processes of vital activity involved in the regulation 
of cellular metabolism, water-salt metabolism, as well as to 
generate excitation. The activity of Na / K-ATPase is depen-
dent on the ATP content in the cell [64]. A decrease in Na+, 
K+-АТРase activity leads to slower nerve impulses and may 
be accompanied by a loss of pain sensitivity [65].
Another mechanism that contributes to the reduction of 
nociception in the early stages of cancer is probably related 
to a change in the functionality of the cyclase systems. In 
particular, some solid tumours show a deficiency of adenyl-
ate cyclase in the intermembrane space [61]. The authors 
[66, 67] have noted the direct inhibitory effect of calcium 
ions on isoforms 5, 6 of adenylate cyclase. In the light of the 
above data on the increase of cytosolic calcium level in blast 
cells, remarks of the authors [68] who report a marked de-
crease in acute and chronic pain intensity via blocking ade-
nylate cyclase activity in animal models are very interesting.
Immune system and sensory influences
One of the most significant milestones of modern immu-
nology is the formation of a scientifically based concept of 
innate and adaptive immunity. From an evolutionary point 
of view, innate immunity is an earlier protective mechanism 
inherent in virtually all multicellular organisms. Being he-
reditary, this structure provides protection of the individual 
from various microorganisms and endogenous derivatives 
of tissue disintegration, activating for several minutes or 
hours. All components of innate immunity are invariably 
inherited and are not genetically modified throughout life. 
Functioning of this protective system is provided by numer-
ous cellular elements (eosinophils, mast cells, macrophages, 
neutrophils, basophils, NK cells), microglial cells – resident 
macrophages of the central nervous system (CNS) and hu-
moral factors (lysozyme, cytokines, complement, acute-
phase proteins (APPs), cationic antimicrobial peptides, etc.) 
[69].  C. Janeway formulated the principle of innate immu-
nity at the end of the 20th century by introducing the con-
cept of pathogen-associated molecular patterns (PAMPs), 
which are encoded in the genomes of bacteria and absent in 
the genome of macroorganisms. The most studied PAMPs 
are DNA and RNA viruses and bacteria, flagellin, bacte-
rial wall lipopolysaccharides (LPS), glycolipids, lipoteichoic 
acid (LTA), lipoproteins, zymosan fungi [70, 71]. It has also 
been found that many macroorganism-derived compounds 
formed during cytolysis can act as PAMPs (fibrinogen, 
heat shock proteins, fibronectin, etc.) – damage-associated 
molecular patterns (DAMPs) [72, 73, 74]. Identification of 
antigens by the cells of the innate immune system is car-
ried out by receptor formations that distinguish the pat-
tern of pathogens (pattern recognition receptors – PRRs). 
Pattern-recognition receptors (PRRs) are divided into three 
classes according to their function: signaling, endocytic and 
secreted. Signaling PRRs contribute to the transmission of 
the signal into the cell nucleus to activate the genes of adap-
tive immunity. Endocytic PRRs mediate the damage of the 
pathological agent in the lysosomes of macroorganism cells. 
Secreted PRRs act as opsonins, “marking” antigenic struc-
tures and contributing to the process of phagocytosis [75]. 
One of the most significant elements of the class of PRRs are 
Toll-like receptors (TLRs) [76]. These structures were first 
discovered in 1997 in mammals [77]. Receptors of this class 
are widely represented in various cells of organs and body 
systems (monocytes, leukocytes, fibroblasts, endothelium, 
epithelium, cardiomyocytes, B cells [78], mast cells [79], 
natural killer cells (NK cells) [80]. TLRs are common in var-
ious cell populations of the central nervous system (CNS): 
dendritic cells (DCs) [81], neurons [82], astrocytes [83] and 
oligodendrocytes [84], and glia [85]. This feature provides 
a significant link between the innate immune system and 
the CNS. The abundance of TLRs in pain responsive regions 
makes them a critical potential component of pain signal-
ing. 
Glia is a collection of accessory cells of the neural tis-
sue, accounting for more than 70% of all cells found within 
the brain and spinal cord [86]. Glial cells have been recog-
nized as key mediators of the innate immune responses in 
the CNS and play a major role in the clearance of cellular 
detritus and immune surveillance [86, 87]. It should be 
noted that complementary glial cells are important modula-
tors of pain. According to scientists Piccinini AM. et al. [89]; 
Scholz Z., et al. [90], damage-associated molecular patterns 
(DAMPs) can activate glial cells through TLR receptors, 
which have a well-established role in pathological pain. On 
the other hand, it has been proven that some tricyclic com-
pounds that are commonly used for clinical neuropathic 
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pain treatment possess significant TLR4 inhibitory activity 
and can reduce sensitivity (Hutchinson MR, et al.,) [91]. In 
preclinical experiments, the study of pain mechanisms re-
vealed interesting features of expression of TLRs [92]. After 
the induction of peripheral inflammation (plantar adminis-
tration of Complete Freund’s Adjuvant (CFA) in laboratory 
rats), the transcriptional level of mRNA TLR4 significantly 
increased within a short period of time (4 hours) in vari-
ous regions of the central nervous system. This indicator 
has remained high for 14 days, and persisted even when 
the emerging signs of experimental allodynia disappeared. 
In this context, I would like to mention the remarks of re-
searchers [93], who noted the activation of microglial cells 
as a result of peripheral nerve damage (peripheral neuropa-
thy). The authors noted an interesting feature of glia – once 
activated microglial cells can remain in a “sensitized” state. 
Similar changes in the properties of glial cells were noted 
not only as a result of peripheral nerve damage, but also as 
a result of stress factors [94].  According to Ferraz CC. et 
al. [95], Diogenes A. et al. [96], the functionality of TLR4 
depends on the amount of intracellular calcium and the lev-
el of sensitization of TRPV1.Given the above information 
about the ability of tumor cells to suppress the functionality 
of membrane calcium channels [37], we can assume a local 
(tumor) inhibitory effect on TLR systems. Perhaps this phe-
nomenon ultimately operates systemically, inducing a spe-
cial “hyposensitized” state of glia. Probably the indirect con-
firmation of this assumption is the observations of scientists 
Tashiro M, et al. [97], who studied the brain of 19 patients 
with various types of cancer (except for brain cancer) using 
positron emission tomography. The results of the study were 
compared with images of 17 patients with benign diseases. 
The authors noted a decrease in regional cerebral glucose 
metabolism in separate areas of the CNS – limbic system, 
thalamus, hippocampus, basal ganglia, etc. According to 
them, the psychological deficit in cancer patients is asso-
ciated with abnormalities of regional brain metabolism in 
the limbic system. Given the specifics of our research, we 
consider it worthwhile first of all to note the reduction of 
regional cerebral glucose metabolism in the thalamus. This 
structure not only retransmits all sensory and motor infor-
mation from the sense organs, but also performs primary 
processing and thus filters the incoming sensory informa-
tion before transferring it to the cortex of the large hemi-
spheres [98]. The given changes in such an important area of 
the central nervous system as the thalamus most likely have 
a negative impact on its functionality and lead to sensory 
disorders. 
Recent studies indicate the probability of synthesis and 
secretion of identical regulatory peptides (substance P (SP), 
VIP, enkephalins, cholecystokinin, somatostatin, beta-
endorphin, lipotropins, angiotensin, calcitonin) by cells of 
various organs and tissues. The affinity of these compounds 
to the receptors has been discovered, and it looks common 
in many body systems. Considering the latter, substitution 
of the concept of nervous, immune, endocrine and humoral 
modulation by the term “regulatory continuum” has been 
proposed [99]. 
According to the postulates of integrative medicine, the 
conjugated interaction of nociception and immunity now 
occurs both at all levels of the nervous system, and in all 
organs and components of the immune system. In the last 
process, almost all known hormones, neurotransmitters and 
cytokines are involved. Thus, the receptors of neurotrans-
mitters involved in the occurrence and conduct of pain im-
pulses also affect the functionality of immune cells. At the 
same time, a number of hormones, cytokines and other bio-
active compounds secreted by lymphoid cells, changes the 
excitability of nerve fibres [100].
Early studies on the role of the immune system in the 
development of cancer indicate a circular infiltration of im-
mune cells by tumours [101, 102, 103]. The authors have 
convincingly demonstrated tumour stimulation by immune 
system cells and neoplastic progression [104, 105]. Stimu-
lation of these structures occurs as a means of adrenergic 
influences of macroorganism and cytokines produced by 
a cancerous tumour [106, 107]. The suppressor effect in 
prostate cancer on the population of T-killers [108] was 
also proven. In the inflammatory process, the release of 
proangiogenic factors and enzymes that change the cellular 
matrix and promote invasion and metastasis occurs in infil-
tration of the tumour microenvironment by immunocom-
petent cells [109]. 
On the other hand, besides these sensitizing cytokines, 
immunocompetent cells (ICC) – macrophaghes, neutro-
phils, lymphocytes – can also produce opioid peptides that 
provide desensitization of peripheral nociceptors [110, 111, 
112, 113].
Inflammation of peripheral tissues leads to increased 
synthesis and axonal transport of opiate receptors in dorsal 
root ganglion neurons, which causes an enhanced analgesic 
efficacy of peripherally active opioids. Once secreted, opioid 
peptides activate peripheral opiate receptors and produce 
analgesia by inhibiting the excitability of sensory nerves. 
These effects occur without central untoward side effects 
such as depression of breathing, clouding of consciousness, 
or addiction [114, 115]. This peripheral antinociceptive sys-
tem with ICC may allow the neoplasm to remain asymp-
tomatic for a while. In this context, we consider interesting 
the observations of the authors [116] who have noted that 
Mycobacterium tuberculosis activates formyl peptide re-
ceptor (FPR) on neutrophils, resulting in tonic secretion of 
opioid peptides from neutrophils and in a decreased inflam-
matory pain.
Earlier it was suggested that malignant tumour forma-
tion is analogous to a certain “killer organ” [117, 118].  Suc-
cessful progression of this process is provided with clearly 
outlined strategies. Some of the most well-known strategies 
are changes in the microenvironment by isolating specific 
metabolites and tumour secretion of growth factors, growth 
of malignant blastemal cells during the deterioration of me-
dium conditions, immune-suppression by developing an 
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antigenic simplification, divergence and antigenic reversion 
[119]. As is known, a long asymptomatic flowing provides 
oncogenesis with a “special” effect and perhaps outlines an 
additional strategy.
Conclusions
Taking into account the aforementioned literature data 
about oncogenesis, it may be assumed the presence of a new 
complex pathogenetic pattern that ensures the asymptom-
atic evolution of PCa. A better coverage of this data may 
facilitate further search for early markers of the disease.
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